{"contentid": 488535, "importid": NaN, "name": "Yarrow Biotechnology in-licenses ProQR\u00e2\u0080\u0099s ASO technology", "introduction": "Life-cycle investment firm RTW Investments and Dutch biotech ProQR Therapeutics today announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR\u00e2\u0080\u0099s antisense oligonucleotide (ASO) technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target.", "content": "<p>Life-cycle investment firm RTW Investments and Dutch biotech ProQR Therapeutics (Nasdaq: PRQR) today announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR&rsquo;s antisense oligonucleotide (ASO) technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target.&nbsp;</p>\n<p>Yarrow is&nbsp;focused on&nbsp;developing ASO-based therapeutics for disorders with high unmet need. News of the deal pushed ProQR&rsquo;s shares up 5.4% to $6.70 in pre-market trading today, though the stock drifted off as regular trading began.</p>\n<p>Dr Roderick Wong, managing partner and chief Investment Officer of RTW, said: &ldquo;We believe RNA-based therapies hold&nbsp;great promise to treat genetically-defined&nbsp;diseases. We are excited to&nbsp;partner with ProQR to in-license the first target&nbsp;to&nbsp;be developed&nbsp;in&nbsp;Yarrow&rsquo;s pipeline.&rdquo;</p>\n<h2><strong>Deal provides up to $115 million payments to ProQR</strong></h2>\n<p>Under the terms of the agreement, ProQ<a id=\"save\" class=\"save\" title=\"Save\"></a>SaveR is eligible to receive up to $115 million of upfront and milestone payments, plus single digit percentage royalties on the&nbsp;net&nbsp;sales of any resulting products during the royalty term. ProQR will also have the right to receive an undisclosed percentage of equity in the form of shares of common stock of Yarrow. ProQR will be responsible for certain pre-clinical activities with reimbursement for the research costs by Yarrow, while Yarrow will be responsible for continuing development of the program and commercialization activities.</p>\n<p>Gerard Platenburg, chief innovation officer at ProQR, will join Yarrow&rsquo;s board of directors.</p>\n<p>Peter Fong, head of company creation at RTW, said: &ldquo;Our partnership with ProQR fits perfectly into Yarrow&rsquo;s mission to develop first-in-class ASO-based therapies for genetically-defined diseases. We look forward to a long and productive partnership.&rdquo;</p>\n<p>Daniel De Boer, founder and chief executive of ProQR, said: &ldquo;As we focus ProQR on our core genetic eye disease strategy, we are pleased to partner with Yarrow to advance our technology in applications outside the eye, while generating value from this partnership and the broad applicability of our platform.&rdquo;</p>", "date": "2021-05-04 15:00:00", "meta_title": "Yarrow Biotechnology in-licenses ProQR\u00e2\u0080\u0099s ASO technology", "meta_keywords": "Yarrow Biotechnology, ProQR Therapeutics, RTW Investments, ASO technology, License, Non-ophthalmic", "meta_description": "Yarrow Biotechnology in-licenses ProQR\u00e2\u0080\u0099s ASO technology", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-04 14:58:55", "updated": "2021-05-04 15:08:00", "access": NaN, "url": "https://www.thepharmaletter.com/article/yarrow-biotechnology-in-licenses-proqr-s-aso-technology", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "proqr_large.png", "image2id": "proqr_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Ophthalmics", "topic_tag": "Companies, mergers and acquisitions, Deals, Licensing, One to Watch Companies, Research", "geography_tag": "Netherlands, USA", "company_tag": "ProQR Therapeutics N.V., Rtw investments, Yarrow Biotechnology", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-04 15:00:00"}